Pharmacokinetics and metabolism of EXP921, a novel cognitive enhancer, in rats

Drug Metabolism and Disposition

Volumn 24, Issue 2, 1996, Pages 172-179

  Wong, Y N ^a   Quon, C Y ^a,b   Holm, K A ^a   Burcham, D L ^a   Frey, N L ^a   Huang, S M ^a   Lam, G N ^a  

^a DUPONT COMPANY   (United States)

^b Biodevelopment Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,5 BIS(4 PYRIDINYLMETHYL) 5H CYCLOPENTA[2,1 B:3,4 B']DIPYRIDINE; 5,5 BIS(4 PYRIDINYLMETHYL) 5H CYCLOPENTA[2,1 B:3,4 B']DIPYRIDINE N' OXIDE; DRUG METABOLITE; EXP 696; EXP 921; NOOTROPIC AGENT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG OXIDATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ALZHEIMER DISEASE; ANIMALS; DRUG ADMINISTRATION SCHEDULE; HALF-LIFE; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MOLECULAR STRUCTURE; NOOTROPIC AGENTS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0030042976     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. R. Katzman and L. J. Thal: Neurochemistry of Alzheimer's disease. In "Basic Neurochemistry: Molecular Cellular, and Medical Aspects" (G. J. Siegel, B. Agranoff, R. W. Albers, and P. Molinoff. eds.), 4th ed., pp. 827-838. Raven Press. New York, 1989.
2. E. D. Levin, S. R. McGurk, J. E. Rose, and L. L. Butcher: Cholinergicdopaminergic interactions in cognition performance. Behav. Neural Biol. 54, 271-299 (1990).
3. C. M. Lopez, S. Govoni, F. Battaini, S. Bergamaschi, A. Longoni, C. Giaroni, and M. Trabucchi: Effect of a new cognition enhancer, alpha-glycerylphosphorylcholine, on scopolamine-induced amnesia and brain acetylcholine. Pharmacol Biochem. Behav. 39, 835-840 (1991).
4. P. Etienne, S. Gauthier, G. Johnson, B. Collier, T. Mendis, D. Dastoor, M. Cole, and H. F. Muller: Clinical effects of choline in Alzheimer's disease. Lancet 1, 508-509 (1978).
5. E. Hollander, M. Davidson, R. C. Mohs, T. B. Horvath, B. M. Davis, Z. Zemishlany, and K. L. Davis: RS86 in the treatment of Alzheimer's disease: cognitive and biological effects. Biol. Psychiatry 22, 1067-1078 (1987).
6. V. Kumazr: Efficacy and side effects of THA in Alzheimer's disease patients. In "Current Research in Alzheimer Therapy" (E. Giacobini and R. Becker, eds.), pp. 225-229. Taylor and Francis, New York, 1988.
7. W. K. Summers, L. V. Majovski, G. M. Marsh, K. Tachiki, and A. Kling: Oral tetrahydroaminoacridine in long term treatment of senile dementia Alzheimer type. N. Engl. J. Med. 315, 1241-1245 (1986).
8. S. Gauthier, R. Bouchard, A. Lamontagne, P. Bailey, H. Bergman, J. Ratner, Y. Tesfaye, M. Saint-Martin, Y. Bacher, L. Carrier, R. Charbonneau, M. Clarfield, B. Collier, D. Dastoor, L. Gauthier, M. Germain, C. Kissel, M. Krieger, S. Kushnir, H. Mason, J. Morin, N. Vasavan, L. Neirinck, and S. Suissa: Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. N. Engl. J. Med 322, 1272-1276 (1990).
9. M. G. Baxter, K. W. Rohrbach, S. W. Tam, R. S. Zaczek, K. M. Frick, S. Golski, R.-Q. Wan, and D. S. Olton: Effects of linopirdine (DuP996) and X9121 on age-related memory impariments and on the cholinergic system. Drug Dev. Res. 31, 186-196 (1994).
10. W. F. Ebling and W. J. Jusko: The determination of essential clearance, volume, and residence time parameters of recirculating metabolic systems: the reversible metabolism of methylprednisolone and methylprednisone in rabbits. J. Pharmacokinet. Biopharm. 14, 557-599 (1986).
11. B.-S. Kuo, J. C. Poole, K.-K. Hwang, and H. Cheng: Pharmacokinetics and metabolic interconversion of intravenous 4-amino-5-chloro-2-[(methyl-sulfinyl)ethoxy]-N-[2-(diemylamino)ethyl]benzamide and its sulfide and sulfone metabolites in rats. J. Pharm. Sci. 82, 694-698 (1993).
12. Y. N. Wong, D. L. Burcham, K. A. Holm, and S.-M. Huang: The pharmacokinetics of EXP921 and an N-oxide metabolite in monkey. ISSX Proc. 2, Abstract 201 (1992).
13. M. H. Bickel: The pharmacology and biochemistry of N-oxides. Pharmacol Rev. 21, 325-355 (1969).
14. A. Nagy and T. Hansen: The kinetics of imipramine N-oxide in man. Acta Pharmacol. Toxicol. 42, 58-67 (1978).
15. M. Al-Waiz, R. Ayesh, S. C. Mitchell, J. R. Idle, and R. L. Smith: Disclosure of the metabolic retroversion of trimethylamine N-oxide in humans: a pharmacogenetic approach. Clin. Pharmacol. Ther. 42, 608-612 (1987).
16. H. Tatsumi and O. Kanamitsu: Studies on the biological activity of nicotinic acid N-oxide. I. Fate of nicotinic acid N-oxide in rat. Yakugaku Zasshi 81, 1748-1753 (1961).
17. R. E. McMahon and H. R. Sullivan: Reduction of levopropoxyphene N-oxide to propoxyphene by dogs in vivo and rat liver microsomal fraction in vitro. Xenobiotica 7, 377-382 (1977).
18. T. J. Jaworski, E. M. Hawes, G. McKay, and K. K. Midha: The metabolism of chlorpromazine N-oxide in the rat. Xenobiotica 18, 1439-1447 (1988).
19. T. J. Jaworski, E. M. Hawes, G. McKay, and K. K. Midha: The metabolism of chlorpromazine N-oxide in man and dog. Xenobiotica 20, 107-115 (1990).
20. D. C. Rakestraw, D. A. Bilski, and G. L. Lam: Determination of linopirdine and its N-oxide metabolites in rat plasma by liquid chromatography. J. Pharm. Biomed. Anal. 12, 1056-1061 (1994).
21. S. Diamond, D. Rakestraw, J. O'Neil, G. Lam, and D. Christ Induction of cytochrome P-450 2B and 3A in mice following the dietary administration of the novel cognitive enhancer linopirdine. Drug Metab. Dispos. 22, 65-73 (1994).
22. L. A. Damani and P. A. Crooks: Oxidative metabolism of heterocyclic ring systems. In "Metabolic Basis of Detoxification" (W. B. Jakoby, J. R. Bend, and J. Caldwell, eds.), pp. 69-89. Academic Press, New York. 1982.
23. L. E. Richards, K. F. Blom, and H. J. Pieniaszek: Species differentiationinlinopirdinemetabolism:formationofadespicolyl-pyridinium-N- glucuronide metabolite in humans. ISSX Proc. 4, Abstract 252 (1993).
24. D. Rakestraw: The metabolism of DuP 996 in rats. ISSX Proc. 3, Abstract 19 (1990).